gastroenterology research and practice

Journals | Policy | Permission Gastroenterology Research �

INFORMATION

• For Authors
• For Reviewers
• For Editors
• For Readers
• Admin-login

(For the last 6-month published articles)

  Original Article   Review  Case Report  Short Communication   Letter to the Editor  Editorial

• Online-First

Gastroenterology Research

Gastrointestinal bleeding (GIB) is common in left ventricular assist devices (LVADs) patients, but the optimal screening approach before LVAD implantation is still unclear. The aim of the study was to describe our experience with pre- and post-LVAD implantation endoscopic screening and subsequent GI bleeding in this cohort.

Guidelines recommend using percutaneous endoscopic gastrostomy (PEG) for dysphagia after 2 weeks of stroke onset. We aimed to study the impact of PEG timing on outcomes in patients with ischemic stroke.

akotsubo cardiomyopathy is classically associated with emotional stress in middle-aged women. In clinical practice, physical stressors are a more common cause of Takotsubo cardiomyopathy.

Abnormal video capsule endoscopy (VCE) findings often require intervention with double balloon enteroscopy (DBE). Accurate VCE reporting is important for procedural planning. In 2017 the American Gastroenterological Association (AGA) published a guideline that included recommended elements for VCE reporting.

In gastric cancer (GC) patients without imaging evidence of distant metastasis, diagnostic staging laparoscopy (DSL) is recommended to detect radiographically occult peritoneal metastasis (M1). DSL carries a risk for morbidity and its cost-effectiveness is unclear.

Vol. 17, No. 1, Feb 2024

Table of contents, original article, case report.

Gastroenterology Research and Practice

Subject Area and Category

• Gastroenterology

Hindawi Publishing Corporation

Publication type

1687630X, 16876121

Information

How to publish in this journal

The set of journals have been ranked according to their SJR and divided into four equal groups, four quartiles. Q1 (green) comprises the quarter of the journals with the highest values, Q2 (yellow) the second highest values, Q3 (orange) the third highest values and Q4 (red) the lowest values.

The SJR is a size-independent prestige indicator that ranks journals by their 'average prestige per article'. It is based on the idea that 'all citations are not created equal'. SJR is a measure of scientific influence of journals that accounts for both the number of citations received by a journal and the importance or prestige of the journals where such citations come from It measures the scientific influence of the average article in a journal, it expresses how central to the global scientific discussion an average article of the journal is.

Evolution of the number of published documents. All types of documents are considered, including citable and non citable documents.

This indicator counts the number of citations received by documents from a journal and divides them by the total number of documents published in that journal. The chart shows the evolution of the average number of times documents published in a journal in the past two, three and four years have been cited in the current year. The two years line is equivalent to journal impact factor ™ (Thomson Reuters) metric.

Evolution of the total number of citations and journal's self-citations received by a journal's published documents during the three previous years. Journal Self-citation is defined as the number of citation from a journal citing article to articles published by the same journal.

Evolution of the number of total citation per document and external citation per document (i.e. journal self-citations removed) received by a journal's published documents during the three previous years. External citations are calculated by subtracting the number of self-citations from the total number of citations received by the journal’s documents.

International Collaboration accounts for the articles that have been produced by researchers from several countries. The chart shows the ratio of a journal's documents signed by researchers from more than one country; that is including more than one country address.

Not every article in a journal is considered primary research and therefore "citable", this chart shows the ratio of a journal's articles including substantial research (research articles, conference papers and reviews) in three year windows vs. those documents other than research articles, reviews and conference papers.

Ratio of a journal's items, grouped in three years windows, that have been cited at least once vs. those not cited during the following year.

Leave a comment

Name * Required

Email (will not be published) * Required

* Required Cancel

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

Follow us on @ScimagoJR Scimago Lab , Copyright 2007-2022. Data Source: Scopus®

Cookie settings

Cookie Policy

Legal Notice

Privacy Policy

• Paper Archives
• Journal Indexing
• Research Conference
• Add Journal

Searching By

• Search More ...

Description

Last modified: 2014-05-18 22:51:10

• No Archives

Advertisement

Gastroenterology Research and Practice Latest Publications

Total documents, published by hindawi limited.

• Latest Documents
• Most Cited Documents
• Contributed Authors
• Related Sources
• Related Keywords

Futuristic Developments and Applications in Endoluminal Stenting

Endoscopic stenting is a well-established option for the treatment of malignant obstruction, temporary management of benign strictures, and sealing transmural defects, as well as drainage of pancreatic fluid collections and biliary obstruction. In recent years, in addition to expansion in indications for endoscopic stenting, considerable strides have been made in stent technology, and several types of devices with advanced designs and materials are continuously being developed. In this review, we discuss the important developments in stent designs and novel indications for endoluminal and transluminal stenting. Our discussion specifically focuses on (i) biodegradable as well as (ii) irradiating and drug-eluting stents for esophageal, gastroduodenal, biliary, and colonic indications, (iii) endoscopic stenting in inflammatory bowel disease, and (iv) lumen-apposing metal stent.

Development and Application of Magnetically Controlled Capsule Endoscopy in Detecting Gastric Lesions

In the past 20 years, several magnetically controlled capsule endoscopes (MCCE) have been developed for the evaluation of gastric lesions, including NaviCam (ANKON), MiroCam-Navi (Intromedic), Endocapsule MGCE (Olympus and Siemens), SMCE (JIFU), and FAMCE (Jinshan). Although limited to observing esophageal and duodenal lesions and lacking the ability of biopsy, MCCE has the advantages of comfort, safety, no anesthesia, no risk of cross-infection, and high acceptability. Several high-quality RCTs showed that the diagnostic accuracy of MCCE is comparable to the traditional gastroscopy. Due to the nonnecessity of anesthesia, MCCE may be more suitable for the elderly with obvious comorbidities as well as children. With more evidences accumulated and more innovative technologies developed, MCCE is expected to be an important tool for screening of early gastric cancer or the diagnosis of gastric diseases.

Exploration of the Potential Mechanisms of Wumei Pill for the Treatment of Ulcerative Colitis by Network Pharmacology

Background. Wumei pill (WMP) has a long history of colitis treatment in China, but the protective mechanisms have not been elucidated. To uncover the potential mechanisms of WMP against ulcerative colitis (UC), the network pharmacology approach was utilized in this study. Methods. Public databases were utilized to identify the potential targets of WMP and genes related to UC. Based on the identified overlapping common targets, drug-ingredient-target gene network, Gene Ontology (GO) analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, and protein-protein interaction (PPI) analysis were conducted. Molecular docking was carried out to verify the selected key active ingredients and core targets. Results. 129 active ingredients and 622 target genes were obtained. The drug-ingredient-target gene network revealed 52 active ingredients of WMP acting on 73 targets related to UC. GO analysis revealed that biological processes were mainly associated with oxidative stress, such as, reactive oxygen species metabolic processes, response to oxidative stress, cellular response to oxidative stress, response to reactive oxygen species, and regulation of reactive oxygen species metabolic processes. KEGG analysis revealed that the immune- and inflammation-related pathways, tumor-related signaling pathways, and microbial infection-related signaling pathways were the most significant. PPI network identified 13 core target genes. The molecular docking results indicated the formation of stable bonds between the active ingredients and core target genes. Conclusions. The approach of network pharmacology reveals the key ingredients, potential core targets, and biological process of WMP in the treatment of UC. The mechanisms of action of WMP involve anti-inflammation, antioxidation, and modulation of immunity, which provides evidence for the therapeutic role of WMP in UC.

TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer

Objective. To evaluate the effectiveness and safety of TAS-102 monotherapy and combination therapy with bevacizumab in the treatment of metastatic colorectal cancer. Methods. The PubMed, Web of Science, MEDLINE, and Cochrane Library databases were searched for the literature on TAS-102 treatment of metastatic colorectal cancer. Extracted data include median overall survival (mOS), median progression-free survival (mPFS), and the incidence of adverse events for meta-analysis. Results. Our study found that the mOS of patients treated with TAS-102 monotherapy was 6.95 (95% CI: 6.26-7.72) months and the mPFS was 2.53 (95% CI: 2.31-2.78) months. The mOS in patients treated by TAS-102 combined with bevacizumab was 10.41 (95% CI: 8.40-12.89) months, and the mPFS is 4.35 (95% CI: 3.05-6.20) months. In the control experiment, the patients’ mOS and mPFS were improved. TAS-102+B vs. TAS-102 ( OR = 0.41 , 95% CI: 0.18-0.93; OR = 0.72 , 95% CI: 0.63-0.83) and TAS-102 vs. placebo ( OR = 0.44 , 95% CI: 0.29-0.67; OR = 0.51 , 95% CI: 0.42-0.62) were studied to actively prevent the occurrence of neutropenia, leukopenia, febrile neutropenia, anemia, and vomiting. Conclusion. TAS-102 monotherapy and combination therapy with bevacizumab can significantly improve the survival of patients and prevent specific adverse events from happening.

Risk of Bleeding after Colorectal Endoscopic Resection in Patients with Continued Warfarin Use Compared to Heparin Replacement: A Propensity Score Matching Analysis

The Japan Gastroenterological Endoscopy Society (JGES) guidelines recommend continued warfarin treatment during gastroenterological endoscopic procedures with a high risk of bleeding as an alternative to heparin replacement in patients on warfarin therapy. However, there is insufficient evidence to support the use of warfarin in colorectal endoscopic resection (ER). The present study is aimed at verifying the risk of bleeding after ER for colorectal neoplasia (CRN) in patients with continued warfarin use. This was a single-center retrospective cohort study using clinical records. We assessed 126 consecutive patients with 159 CRNs who underwent ER (endoscopic mucosal resection, 146 cases; endoscopic submucosal dissection, 13 cases) at Hiroshima University Hospital between January 2014 and December 2019. Patients were divided into two groups: the heparin replacement group (79 patients with 79 CRNs) and the continued warfarin group (47 patients with 80 CRNs). One-to-one propensity score matching was performed to compare the bleeding rate after ER between the groups. The rate of bleeding after ER was significantly higher in the heparin replacement group than in the continued warfarin group for both before (10.1% vs. 1.3%, respectively; P = 0.0178 ) and after (11.9% vs. 0%, respectively; P = 0.0211 ) propensity score matching. None of the patients experienced thromboembolic events during the perioperative period. The risk of bleeding after colorectal ER was significantly lower in patients with continued warfarin use than in those with heparin replacement. Our data supports the recommendations of the latest JGES guidelines for patients receiving warfarin therapy.

Endoscopic Delivery Method Using a Retrieval Net for Patients with Small-Bowel Capsule Endoscopy Stagnation in the Stomach

With the increasing use of capsule endoscopy (CE), screening tests for the small bowel can be performed with minimal invasiveness. However, occasionally, the entire small bowel cannot be observed because of decreased peristalsis of the stomach. For such cases, we perform delivery of CE by an endoscope. We retrospectively examined the usefulness of the endoscopic delivery method using a retrieval net for patients with CE stagnation in the stomach. From 2,270 patients who underwent small-bowel CE at Hiroshima University Hospital from January 2013 to January 2020, 29 consecutive patients (1.3% of the total number) in whom the small bowel could not be observed due to CE stagnation in the stomach at the time of the initial CE underwent the endoscopic delivery method using a retrieval net for secondary small-bowel CE. This study included 16 male (55%) and 13 female (45%) patients with a mean age of 69.2 ± 13.2   years . 11 patients (38%) had a history of gastrointestinal surgical resection. The entire small bowel could be observed in 19 patients (66%), and CE reached the terminal ileum in the remaining patients. A history of gastrointestinal surgical resection was significantly more frequent in the group where the entire small bowel could not be observed. The rate of small-bowel lesion detection was 55% (16/29). There were no adverse events associated with our endoscopic delivery method. Thus, the endoscopic delivery method using a retrieval net for patients with initial CE stagnation in the stomach may be safe and useful for the detection of small-bowel lesions.

p53 Immunohistochemistry Patterns Are Surrogate Biomarkers for TP53 Mutations in Gastrointestinal Neuroendocrine Neoplasms

Aims. The aim of this study was to establish p53 immunohistochemistry (IHC) patterns to predict TP53 mutations in gastrointestinal neuroendocrine neoplasms (GI-NENs) and to determine whether p53 IHC patterns could be used for the differential diagnosis of neuroendocrine neoplasms. Methods. TP53 gene sequencing and p53 IHC were performed on formalin-fixed paraffin-embedded (FFPE) tissue samples from 92 patients diagnosed with GI-NENs from five medical centers. Results. The cohort included 35 well-differentiated neuroendocrine tumors and 57 poorly differentiated neuroendocrine carcinomas. Gene sequencing revealed 38 wild-type TP53 and 54 TP53 mutations. p53 expression was interpreted as follows: pattern A, p53 was absent from all tumor cells; pattern B, scattered and weak p53 expression in 1-20% of tumor cells; and pattern C was subclassified as pattern C1: variable p53 staining intensity in 21-60% of tumor cells and tumor cell nests with focal strong positive p53 staining and pattern C2: strong p53 staining in more than 60% of tumor cells. p53 IHC patterns were evaluated as a binary classifier where pattern B predicted wild-type TP53, and patterns A and C predicted TP53 mutations. The sensitivity, specificity, and overall accuracy of this binary classification to predict TP53 status were 0.963, 0.868, and 0.924, respectively. p53 IHC patterns were also correlated with TP53 mutation types. Most cases with pattern A harboured loss-of-function (LOF) mutations, whereas patterns B and C tended to indicate wild-type TP53 and gain-of-function (GOF) mutations, respectively. Furthermore, most of the well-differentiated NETs showed pattern B, whereas pattern C2 was more common in poorly differentiated NECs. Finally, staining interpretation between different observers also yielded high reproducibility. Conclusions. p53 IHC patterns may be used as predictors of TP53 gene mutations and therefore could be potential surrogate markers for TP53 mutations in GI-NENs and could distinguish between well-differentiated NETs and poorly differentiated NECs.

Prognostic Value of TRPM7 Expression and Factor XIIIa-Expressing Tumor-Associated Macrophages in Gastric Cancer

Purpose. TRPM7 is known to play a key role in tumor progression by regulating cellular proliferation, migration, and invasion in various cancer cell lines. However, there are no comprehensive clinical studies about the effect of TRPM7 expression on gastric cancer (GC) prognosis. In this study, it was aimed at investigating the effect of TRPM7 expression on prognosis in GC patients. Additionally, for the first time, it was investigated whether the density of Factor XIIIa-expressing tumor-associated macrophages (TAMs) in GC has an effect on the biological behaviour of the tumor. Methods. TRPM7 expression and Factor XIIIa-expressing TAM density were immunohistochemically evaluated in paraffin-embedded tumor tissues of 204 GC patients undergoing surgery at a single institution. Results. Tumor size was clearly higher in cases with high TRPM7 expression than those with low expression ( p < 0.001 , Mann-Whitney U ). TRPM7 overexpression was closely related to high depth of tumor invasion ( p < 0.001 , ANOVA), increased lymph node metastasis ( p < 0.001 , ANOVA), and high distant metastasis rate ( p < 0.001 , Mann-Whitney U ). These findings exposed that high TRPM7 expression is effective in the progression and aggressiveness of GC. In addition, while high CD8+ TIL density affects the prognosis positively, it was determined that high Factor XIIIa+ TAM density negatively affects the prognosis of patients with GC. Furthermore, multivariate analyses revealed TRPM7 overexpression was independently related with short overall (HR 9.64, 95% CI 5.74–16.19, p < 0.001 ) and disease-free survival (HR 5.67, 95% CI 3.61-8.92, p < 0.001 ) in GC patients. Conclusions. Our data suggest that high TRPM7 expression is closely related to progressive tumor behaviour in GC and independently negatively affects survival in patients. In addition, it was determined that a high density of Factor XIIIa+ TAMs negatively affects the prognosis of patients with GC.

The Clinicopathological Characteristics and Prognoses of dMMR Gastric Adenocarcinoma Patients

Background. Few studies on the clinicopathological features and prognosis of DNA mismatch repair deficiency (dMMR) gastric cancer (GC) have been reported, and no clear conclusions have been drawn about the factors affecting the prognosis of dMMR GC. The aim of this study was to explore the clinicopathological characteristics and prognoses of dMMR GC patients. Methods. From May 2011 to November 2020, GC patients who underwent surgery with dMMR confirmed by immunohistochemistry (IHC) at the Affiliated Cancer Hospital of Shanxi Medical University were selected. The patients’ clinical and pathological data were collected. The recurrence-free survival (RFS) and overall survival (OS) rates of the patients were determined through follow-up. SPSS 26.0 was used to analyze the patients’ clinicopathological features and prognoses. Results. A total of 162 dMMR GC patients met the inclusion criteria, and the median age was 63.5 years (32–89 years). dMMR GC was more common in males (65% vs. 35%), and most of the cases were stage II (the prevalence of stage I was 22%, that of stage II was 43%, that of stage III was 30%, and that of stage IV was 5%). Most of the lesions were located in the antrum (49%), followed by the cardia (25%). PMS2 and MLH1 (57%) deficiency was most common. Kaplan–Meier analysis showed that factors related to OS were family history ( P = 0.048 ), number of lymph node (LN) metastases ( P < 0.001 ), vascular tumor thrombus ( P < 0.001 ), HER2 expression status ( P = 0.025 ), and clinical stage ( P < 0.001 ). The factors related to RFS included vascular tumor thrombus ( P < 0.001 ), number of LN metastases ( P < 0.001 ), and clinical stage ( P < 0.001 ). Conclusion. In this study, dMMR GC was more common in men, and the median age was 63.5 years. Most of the lesions were in the antrum and showed the combined deletion of MLH1 and PMS2. dMMR GC patients tended to be early stage, and the prognosis of those with early-stage GC was better. dMMR GC patients with vascular tumor thrombus or >6 LN metastases had a high recurrence rate and poor survival outcome.

Export Citation Format

Share document.

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

• View all journals
• Explore content
• About the journal
• Publish with us
• Sign up for alerts
• Research Highlight
• Published: 07 March 2024

In the news

2023 FDA approvals in gastroenterology and hepatology

• Eleni Kotsiliti 1  

Nature Reviews Gastroenterology & Hepatology ( 2024 ) Cite this article

86 Accesses

2 Altmetric

Metrics details

• Drug therapy
• Health services

In 2023 , the Center for Drug Evaluation and Research (CDER) of the US Food and Drug Administration (FDA) approved 55 novel drugs, 4 related to gastroenterology and hepatology.

In 2022 , the new drug approvals included treatments for Helicobacter pylori infection, T2DM blood sugar control in addition to diet and exercise, FGFR2-aberrant intrahepatic cholangiocarcinoma and unresectable hepatocellular carcinoma.

This is a preview of subscription content, access via your institution

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

24,99 € / 30 days

cancel any time

Subscribe to this journal

Receive 12 print issues and online access

195,33 € per year

only 16,28 € per issue

Rent or buy this article

Prices vary by article type

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and affiliations.

Nature Reviews Gastroenterology & Hepatology http://www.nature.com/nrgastro/

Eleni Kotsiliti

You can also search for this author in PubMed   Google Scholar

Corresponding author

Correspondence to Eleni Kotsiliti .

Rights and permissions

Reprints and permissions

About this article

Cite this article.

Kotsiliti, E. 2023 FDA approvals in gastroenterology and hepatology. Nat Rev Gastroenterol Hepatol (2024). https://doi.org/10.1038/s41575-024-00916-1

Download citation

Published : 07 March 2024

DOI : https://doi.org/10.1038/s41575-024-00916-1

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Quick links

• Explore articles by subject
• Guide to authors
• Editorial policies

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Gastroenterology Research and Practice

Journal Abbreviation: GASTROENT RES PRACT Journal ISSN: 1687-6121

About Gastroenterology Research and Practice

You may also be interested in the following journals.

• ► Scandinavian Journal of Gastroenterology
• ► Turkish Journal of Gastroenterology
• ► Gastroenterology
• ► Canadian Journal of Gastroenterology
• ► Pancreatology
• ► Acta Diabetologica
• ► Clinical Gastroenterology and Hepatology
• ► Pancreas

Top Journals in other

• Ca-A Cancer Journal For Clinicians
• Chemical Reviews
• Nature Materials
• Reviews of Modern Physics
• Nature Reviews Molecular Cell Biology
• Annual Review of Astronomy and Astrophysics
• Cancer Discovery
• BMJ-British Medical Journal
• Advanced Energy Materials
• Advances in Optics and Photonics

Journal Impact

• [email protected]
• 125-711-811 125-668-886

Author Guidelines

Journal of Gastroenterology Research and Practice is an open access journal publishes articles covering basic science, clinical and experimental aspects of gastroenterology and digestive system. For journal scope and areas covered, please follow the webpage: https://jjgastro.com/journal-scope.html . All the published manuscripts are archived and available online at https://jjgastro.com/archive.html . Unique DOI is assigned for all manuscripts immediately after the publication for global recognition of author's work. In addition, the journal would allow free and unlimited access (open access) to the published material to attract more readers and increase the no. of citations. Published manuscripts are also promoted in different social and academia platforms for global coverage.

Manuscripts must be prepared in accordance to the guidelines mentioned in "International Committee of Medical Journal Editors". Summary of all such guidelines and all other information required for authors are available here. Authors are requested to follow these instructions while preparing the manuscript for submission to Journal of Gastroenterology Research and Practice.

Manuscript Acknowledgement

All the new submissions are acknowledged within 24 to 48 hours of submission in a belief that the content is unique, neither submitted simultaneously to other journal nor already published. If there is no acknowledgement, please contact us to the email id provided in the contact us web page. Cover letter must be attached along with the manuscript.

Editorial Process

All the new submissions are verified with the internal plagiarism software to avoid plagiarism issues and assigned to handling editor for review and possible publication in the journal. It is the journal editorial office or editor who assigns the manuscript to 1 or 2 external reviewers without providing author's information to avoid biased review. Handling editor will decide the fate of the manuscript based on the reviewer(s) comments.

Decision of the editor includes one of the following parameters:

1. Accept in the current form 2. Accept with minor changes (second review not required) 3. Accept with major changes (second review is mandatory) 4. Reject in current form and can be accepted for review after revision 5. Reject the manuscript

Note: in 3 and 4 cases, revised manuscripts are sent to handling editor for further review. Authors are requested to provide responses to all the comments raised by reviewers/editor for quick second review.

Journal follows 21 day review process and it all depends on availability of editors and reviewers. We start review process immediately after the submission to finish the review in time.

Manuscripts without insufficient data, lack of originality, scientific and technical flaws are rejected and informed to author for further improvement of the manuscript.

Accepted manuscripts are copy edited and sent to production team for PDF production. Journal takes 3 working days to produce the PDF. PDF will be sent to corresponding author prior to publication on the website.

Manuscript Submission

Authors are requested to submit the manuscript along with cover letter via online manuscript submission system. There is no submission fee charged to authors. If you experience any technical issues while registration or uploading the manuscript, please bring them to our notice by contacting the email address provided in the contact us page.

Images: Provide images at the end of the manuscript or attach them separately in word file or image format. JPEG, JPG, PNG, TIFF images of high resolution are accepted. High resolution images helps in building attractive PDF. Figures legend is must for all figures.

Figures should be consecutively numbered according to the order they appear in the manuscript. Symbols, arrow marks or letters used in the images should be clearly visible to the readers. Acknowledge the original source if the figure is already published to avoid copy right complications after publication. Journal reserves the right to crop or reduce the size of the images to the required size.

Tables: Provide tables along with the legends at the end of the manuscript. If there are more than 4 tables, better provide them in new word or excel file. Tables should be consecutively numbered according to the order they appear in the manuscript. Table legends are must for all tables. There is no limit to the number of tables.

Equations and Formulae: For mathematical symbols, Greek letters and other special characters, use normal text or font type "Symbol". MathType is used only for formulae that cannot be produced using normal text.

Cover letter: Signed cover letter must be attached along with the submission. Include conflicts of interest, if any in the cover page. Download the cover letter from the following link:

Consent form: Patient consent form is required if the patient face is visible in the figures used in the manuscript. In all other cases, consent form is not required. Download the consent form from the following link:

Manuscript Preparation:

Prepare your manuscript in word file. Activate page and line numberings. Differentiate headings and side headings properly. Don't add content in headers and footers. All the supplementary files should be provided in separate files. Maintain unique font throughout the manuscript. Increase the font size for headings and side headings.

Your manuscript should contain these headings as they appear in the following order: Title, author names and affiliations, corresponding author information, keywords, abbreviations (if any), abstract, introduction, materials & methods, discussion, conclusion, conflicts of interest, funding sources, acknowledgments, funding, references, figures and tables.

This is the first page of your manuscript. It should contain article type (research/review/case report/clinical image/editorial/other) followed by the manuscript title. Manuscript title should be short and informative. Title should not exceed 75 characters. Don't include abbreviations in the title.

Short or running title should not exceed 50 characters.

Provide list of authors (Last name, First name and initials of middle name) along with the highest academic degree. Their departments and institutions must be attributed. Name, highest degree, current affiliation along with email id and phone number must be provided in corresponding author column.

Abstract page

Keywords: 5 to 8 keywords representing the main content of the manuscript in Keywords section.

Abbreviations: Provide abbreviations along with their full forms under this section.

Introduction

This section should contain the information related to background of your research, purpose, summary of the existing literature and contribution of your work to the existing research.

Materials and methods

This section should include the following: aim and design of your study, characteristics of the data/description of the materials used. Explain the processes, interventions and comparisons involved in your research.

Present the results of your study in text, tables and figures. Describe the most important findings first. Supplementary materials (if any) are published in appendix without disturbing the original manuscript. Do not duplicate the data in graphs and tables.

Conclude your manuscript by providing the importance of your research and its relevance.

Follow Vancouver (numbering style) for references. Reference formatting has different kinds based upon the number of authors or books or the Journal publications etc.,please follow the respective related reference formats:

Journal Article with less than 6 authors: Bonetti F, Pea M, Martignoni G, Zamboni G. PEC and sugar. Am J Surg Pathol. 1992; 16: 307-308.

Journal Article with more than 6 authors: Santi R, Franchi A, Villari D, Paglierani M, Pepi M, Danielli D, et al. Sclerosing variant of PEComa: report of a case and review of the literature. Histol Histopathol. 2012; 27: 1175-1181.

Book References: Gardner JG, Simmons MJ, Snustad PD. Principles of Genetics. 8th edn. New York: John Wiley & Sons. 2006.

Book Chapter: Honn KV, Tang DG, Chen Y. Adhesion molecules and site-specific metastasis. Neri Serneri SS, Gensini GF, Abbate R, Prisco D, editors. In: Thrombosis: An Update. Scientific Press. 1992; 269-303.

Link/URL: National Cancer Institute at National Institutes of Health. [Hyperlinked with www.cancer.gov]

Proceedings of a Conference: Gee JC, Joshi S, Pohl KM, Wells WM, Zollei L, editors. Information Processing in Medical Imaging. Proceedings of 23rd International Conference; 2013 June 28--July 3; CA, USA. New York: Springer, 2013.

PhD Theses/Dissertation: Simonneau A. Gold-Catalyzed Cycloisomerization Reactions through Activation of Alkynes [dissertation]. Springer Theses, 2014.

Datasets: Zheng LY, Guo XS, He B, Sun LJ, Peng Y, Dong SS, et al. Genome data from sweet and grain sorghum (Sorghum bicolor). Giga Science. 2011.

Journal Article Epub ahead of print: Reardon DA, Wen PY. Targeted therapies: Further delineating bevacizumab's response spectrum. Nat Rev Clin Oncol. 2014 [In press].

Journal follows open access model of publication and readers can access, read, download and share the information without subscription. All published manuscripts are licensed under a Creative Commons Attribution 4.0 Unported License. Author retains the copyright of the manuscript and we hold only the publication rights. Submitting the manuscript to the journal implies that author(s) agree to provide publication rights to the journal.

Manuscript word limit

Please see the below table for manuscript word limits:

• Open Access
• Peer Review
• Publication Fee
• Journal scope

An official website of the United States government

The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings
• Browse Titles

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination (UK); 1995-.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].

The use of green coffee extract as a weight loss supplement: a systematic review and meta-analysis of randomised clinical trials.

Review published: 2011 .

Bibliographic details: Onakpoya I, Terry R, Ernst E.  The use of green coffee extract as a weight loss supplement: a systematic review and meta-analysis of randomised clinical trials. Gastroenterology Research and Practice 2011; 2011:382852. [ PMC free article : PMC2943088 ] [ PubMed : 20871849 ]

The purpose of this paper is to assess the efficacy of green coffee extract (GCE) as a weight loss supplement, using data from human clinical trials. Electronic and nonelectronic searches were conducted to identify relevant articles, with no restrictions in time or language. Two independent reviewers extracted the data and assessed the methodological quality of included studies. Five eligible trials were identified, and three of these were included. All studies were associated with a high risk of bias. The meta-analytic result reveals a significant difference in body weight in GCE compared with placebo (mean difference: -2.47 kg; 95%CI: -4.23, -0.72). The magnitude of the effect is moderate, and there is significant heterogeneity amongst the studies. It is concluded that the results from these trials are promising, but the studies are all of poor methodological quality. More rigorous trials are needed to assess the usefulness of GCE as a weight loss tool.

• Cite this Page Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination (UK); 1995-. The use of green coffee extract as a weight loss supplement: a systematic review and meta-analysis of randomised clinical trials. 2011.

Similar articles in PubMed

• The Use of Garcinia Extract (Hydroxycitric Acid) as a Weight loss Supplement: A Systematic Review and Meta-Analysis of Randomised Clinical Trials. [J Obes. 2011] The Use of Garcinia Extract (Hydroxycitric Acid) as a Weight loss Supplement: A Systematic Review and Meta-Analysis of Randomised Clinical Trials. Onakpoya I, Hung SK, Perry R, Wider B, Ernst E. J Obes. 2011; 2011:509038. Epub 2010 Dec 14.
• Review The efficacy of Phaseolus vulgaris as a weight-loss supplement: a systematic review and meta-analysis of randomised clinical trials. [Br J Nutr. 2011] Review The efficacy of Phaseolus vulgaris as a weight-loss supplement: a systematic review and meta-analysis of randomised clinical trials. Onakpoya I, Aldaas S, Terry R, Ernst E. Br J Nutr. 2011 Jul; 106(2):196-202.
• The effect of green-coffee extract supplementation on obesity: A systematic review and dose-response meta-analysis of randomized controlled trials. [Phytomedicine. 2019] The effect of green-coffee extract supplementation on obesity: A systematic review and dose-response meta-analysis of randomized controlled trials. Gorji Z, Varkaneh HK, Talaei S, Nazary-Vannani A, Clark CCT, Fatahi S, Rahmani J, Salamat S, Zhang Y. Phytomedicine. 2019 Oct; 63:153018. Epub 2019 Jul 5.
• Review Pyruvate supplementation for weight loss: a systematic review and meta-analysis of randomized clinical trials. [Crit Rev Food Sci Nutr. 2014] Review Pyruvate supplementation for weight loss: a systematic review and meta-analysis of randomized clinical trials. Onakpoya I, Hunt K, Wider B, Ernst E. Crit Rev Food Sci Nutr. 2014; 54(1):17-23.
• Review Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: An Updated Systematic Review for the U.S. Preventive Services Task Force [ 2018] Review Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: An Updated Systematic Review for the U.S. Preventive Services Task Force LeBlanc EL, Patnode CD, Webber EM, Redmond N, Rushkin M, O’Connor EA. 2018 Sep

Recent Activity

• The use of green coffee extract as a weight loss supplement: a systematic review... The use of green coffee extract as a weight loss supplement: a systematic review and meta-analysis of randomised clinical trials - Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Connect with NLM

National Library of Medicine 8600 Rockville Pike Bethesda, MD 20894

Web Policies FOIA HHS Vulnerability Disclosure

Help Accessibility Careers